Companies · Healthtech
DENVER · Healthtech · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Mariposa Health, Inc./DE — recommendation, valuation, rhythm, risks.→Mariposa Health, Inc./DE looks over-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Mariposa Health, Inc./DE is one of 2138 Healthtech companies tracked from DENVER. By capital raised it ranks in the upper tier (ahead of 89% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 89% of sector peers (real $). Modeled value above 90% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #16 of 98.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Casana Care, Inc. | Series B | $56.4M | $608.0M | 3.68× |
| Mendel Health Inc. | Series B | $52.7M | $570.9M | 3.45× |
| Bicycle Health Inc. | Series B | $61.4M | $492.6M | 2.98× |
| Brave Health, Inc. | Series B | $38.6M | $485.7M | 2.94× |
| Flume Health, Inc. | Series B | $35.9M | $446.0M | 2.70× |
| Healthy America, LLC | Series B | $31.0M | $435.9M | 2.64× |
| Moxe Health Corp | Series B | $34.8M | $404.2M | 2.45× |
| Kintsugi Mindful Wellness, Inc. | Series B | $25.0M | $370.4M | 2.24× |
| Invoq Health, Inc. | Series B | $41.5M | $362.5M | 2.19× |
| Folx Health, Inc. | Series B | $59.3M | $355.7M | 2.15× |
| Recuro Health, Inc. | Series B | $44.2M | $340.0M | 2.06× |
| Orchard Healthcare, Inc. | Series B | $34.8M | $338.9M | 2.05× |
| Mariposa Health, Inc./DE this company | Series B | $40.7M | $301.5M | 1.82× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.0M | 2020-02-01 | $14.9M | $82.6M | 90% |
| Series A | $14.0M | 2021-01-12 | $63.6M | $258.5M | 90% |
| Series A | $3.0M | 2021-02-01 | $13.5M | $53.9M | 90% |
| Series B | $23.7M | 2022-07-25 | $131.8M | $301.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Candace Richardson | — | 2 other | 2022-07 |
| Jenna Ciotti | — | — | 2022-07 |
| Jerrica Kirkley | — | — | 2020-02 |
| Mathew Wetschler | — | — | 2020-02 |
| Matthew Wetschler | — | — | 2022-07 |
Mariposa Health, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Health Recovery Solutions, Inc. | Healthtech | Series B | $40.0M | $505.9M | same sector · same stage |
| Synapse Health, Inc. | Healthtech | Series B | $40.0M | $220.3M | same sector · same stage |
| Invoq Health, Inc. | Healthtech | Series B | $41.5M | $362.5M | same sector · same stage |
| Elligo Health Research, Inc. | Healthtech | Series B | $41.5M | $495.7M | same sector · same stage |
| Nest Healthcare, Inc. | Healthtech | Series B | $42.1M | $109.4M | same sector · same stage |
| Covera Health, Inc. | Healthtech | Series B | $39.4M | $485.3M | same sector · same stage |
| Berry Street Health, Inc. | Healthtech | Series B | $39.2M | $170.0M | same sector · same stage |
| Meru Health Holding Inc. | Healthtech | Series B | $42.4M | $452.7M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Contessa Health, Inc. | Healthtech | Series A | $158.0M | 87% |
| Vivante Health, Inc. | Healthtech | Series B | $281.0M | 86% |
| Rivia Health Inc. | Healthtech | Series A | $57.7M | 85% |
| Acessa Health Inc. | Healthtech | Series A | $203.8M | 84% |
| BetterOff Health, Inc. | Healthtech | Seed | $51.5M | 84% |
| Suneva Medical, Inc. | Healthtech | Series B | $24.9M | 84% |
| Patina Health, Inc. | Healthtech | Series C | $891.7M | 84% |
| Cardiva Medical, Inc. | Healthtech | Series C | $1.2B | 84% |
See where Mariposa Health, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Mariposa Health, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.